NCT04666272 2026-02-19
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
Novartis
Active not recruiting
Clinical Trials
5 trialsNCT06262919 2025-12-30
Special Drug Use-results Surveillance of Tafinlar/Mekinist
Novartis
Recruiting
NCT04961619 2025-12-12
LEAD Melanoma
Novartis
Completed
NCT03944356 2025-03-12
Combi-EU
EuMelaReg gGmbH
Completed
NCT04547946 2023-05-30
Observational Study for Melanoma Adjuvant Treatment With TafinlarĀ® + MekinistĀ® (Dabrafenib + Trametinib)
Novartis
Completed